Trial Profile
HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2014
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Hydroxychloroquine
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HORUS
- 10 Mar 2014 New trial record